Canada’s regulatory approach to drugs for rare diseases: our role in bringing drugs to patients

Canada’s health care system is complex and involves the participation of multiple stakeholders, who all have distinct roles in the planning and delivery of healthcare services. Health Canada’s decision-making role in approving a drug for marketing is distinct from the roles of those who make decisions about price-setting and public drug plan reimbursements.

Data and Resources

Additional Info

Field Value
Last Updated April 17, 2026, 21:35 (UTC)
Created April 17, 2026, 21:35 (UTC)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2018-08-14 00:00:00
open_canada_keywords {"fr": ["L’approche réglementaire du Canada", "les médicaments contre les maladies rares", "notre rôle dans la fourniture de médicaments aux patients"], "en": ["Canada’s regulatory approach", "drugs for rare-diseases", "our-role in-bringing drugs-to-patients"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Médicaments utilisés pour soigner les maladies rares en Canada: notre rôle dans la fourniture de médicaments aux patients
update_frequency as_needed